Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED
精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

NOTICE OF SPECIAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that a special general meeting ("**Meeting**") of Extrawell Pharmaceutical Holdings Limited ("**Company**") will be held at Room 1, United Conference Centre, 10/F., United Centre, 95 Queensway, Admiralty, Hong Kong on Monday, 30 November 2026 at 10:00 a.m. for the purposes of considering and, if thought fit, passing the following special resolution of the Company:

SPECIAL RESOLUTION

"**THAT** subject to and conditional upon fulfilment of the conditions ("**Conditions**") set out in the section headed "Conditions of the Proposed Transactions" in the circular of the Company dated 6 November 2026 ("**Circular**"), a copy of which has been tabled at the meeting marked "A" and initialled by the chairman of the Meeting for the purpose of identification, with effect from the second Business Day (as defined in the Circular) immediately following the date on which this resolution is passed or the Conditions are fulfilled (whichever is later):

(a) every twenty (20) issued and unissued existing shares of the Company ("**Existing Shares**") of par value of HK$0.01 each in the share capital of the Company be consolidated into one (1) consolidated share ("**Consolidated Share**") of par value of HK$0.20 in the share capital of the Company ("**Share Consolidation**");

(b) the total number of Consolidated Shares in the issued share capital of the Company immediately following the Share Consolidation be and is hereby rounded down to a whole number by cancelling any fraction in the issued share capital of the Company arising from the Share Consolidation ("**Rounding**");

* *For identification purpose only*

(c) the issued and paid-up share capital of the Company be reduced by cancelling the paid-up capital of the Company to the extent of HK$0.19 on each of the then issued Consolidated Shares so that the par value of each issued Consolidated Share will be reduced from HK$0.20 to HK$0.01 (each such reduced ordinary share, a "**New Share**") (which together with the Rounding, "**Capital Reduction**");

(d) each of the then authorised but unissued Consolidated Shares of par value of HK$0.20 be sub-divided into twenty (20) New Shares of par value of HK$0.01 each ("**Share Sub-division**" which together with the Share Consolidation and the Capital Reduction, "**Proposed Transactions**") so that following the Proposed Transactions, the authorised share capital of the Company will remain at HK$200,000,000 and divided into 20,000,000,000 New Shares of par value of HK$0.01 each and the issued share capital of the Company will be reduced from an amount of between HK$29,000,000 and HK$40,300,000 by an amount of between HK$27,550,000 and HK$38,285,000 to an amount of between HK$1,450,000 and HK$2,015,000;

(e) the credit arising from the Capital Reduction be entirely transferred to the contributed surplus account of the Company within the meaning of the Companies Act 1981 of Bermuda (as amended) ("**Contributed Surplus Account**") and the board of directors of the Company ("**Directors**") or a committee thereof be and are hereby authorised to use the amount then standing to the credit of the Contributed Surplus Account to eliminate or set off the accumulated losses of the Company which may arise from time to time and/or to pay dividend and/or to make any other distribution out of the Contributed Surplus Account from time to time without further authorisation from the shareholders of the Company and/or to use the credit in such other manner as may be permitted under the bye-laws of the Company in effect from time to time and all applicable laws without further authorisation from the shareholders of the Company and all such actions in relation thereto be approved, ratified and confirmed;

(f) fractional Consolidated Shares will not be issued to holders of the same and the Directors be and are hereby authorised to make arrangements for the settlement and disposal of fractional entitlements, if any, arising from or in connection therewith and, in particular (but without prejudice to the generality of the foregoing), by aggregating any fractional entitlements arising as a result thereof and selling the same for the benefit of the Company in such manner and on such terms as the Directors may think fit; and

(g) any one Director be and is hereby authorised to do all such acts and things and sign, execute and deliver all documents (including affixing the common seal of the Company if appropriate) he/she may, in his/her absolute discretion, consider necessary, appropriate, desirable or expedient for the purpose of, or in connection with, the implementation of or giving effect to or the completion of any matters relating to the Proposed Transactions and all transactions contemplated thereunder."

By the order of the board of directors of
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 6 November 2026

Registered office:
Richmond House
12 Par-la-Ville Road
Hamilton HM 08
Bermuda

Head office and principal place of business in Hong Kong:
Suites 2206–08, 22/F
FWD Tower, Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

Notes:

1. A member of the Company entitled to attend and vote at the Meeting is entitled to appoint in written form one or, if he is the holder of two or more shares ("**Shares**") of the Company, more proxies to attend and vote instead of him. A proxy need not be a member of the Company.

2. In the case of joint holders of Shares, any one of such joint holders may vote, either in person or by proxy, in respect of such Shares as if he/she were solely entitled thereto, but if more than one of such joint holders are present at the Meeting, personally or by proxy, that one of the said persons so present whose name stands first in the register in respect of such Shares shall alone be entitled to vote in respect thereof.

3. A form of proxy for use at the Meeting is published on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and that of the Company (http://www.extrawell.com.hk). In order to be valid, the form of proxy must be in writing under the hand of the appointor or of his attorney duly authorised in writing, or if the appointor is a corporation, either under seal, or under the hand of an officer or attorney duly authorised, and must be deposited at the Company's branch share registrar and transfer office in Hong Kong ("**Branch Registrar**"), Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy thereof) before 10:00 a.m. on Saturday, 28 November 2026 or not less than 48 hours before the time fixed for holding the Meeting (or any adjournment thereof).

4. The record date for determining the entitlement of members to attend and vote at the Meeting will be Monday, 30 November 2026. The register of members of the Company will be closed from Wednesday, 25 November 2026 to Monday, 30 November 2026 (both days inclusive), during which period no transfer of Shares will be effected. In order to be eligible to attend and vote at the Meeting, all transfers of Shares accompanied by the relevant share certificates must be lodged with the Branch Registrar at the above address by no later than 4:30 p.m. on Tuesday, 24 November 2026.

5. Delivery of an instrument appointing a proxy should not preclude a member from attending and voting in person at the Meeting (or any adjournment thereof) and in such event, the instrument appointing a proxy shall be deemed to be revoked.

6. This notice has been printed in English and Chinese. In the event of any inconsistency, the English text of this notice shall prevail over its Chinese text.

As at the date of this notice, the executive directors of the Company are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Wu Xiangyun, and the independent non-executive directors of the Company are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.